News & Events about Indaptus Therapeutics Inc.
Globe Newswire
4 months ago
NEW YORK, Sept. 06, 2022 (GLOBE NEWSWIRE) -- Indaptus Therapeutics, Inc. (Nasdaq: INDP) announced today that Jeffrey A. Meckler, Chief Executive Officer will present a corporate overview at the 24th Annual H.C. Wainwright Global Investment Conference. The conference is being held on September 12 14 ...
Globe Newswire
5 months ago
U.S. Food and Drug Administration (FDA) ClearedInvestigational New Drug (IND) Application for Decoy20 On Track to Initiate Phase 1 Clinical Trial of Decoy20 for Treatment of Solid Tumors in 2022 NEW YORK, Aug. 08, 2022 (GLOBE NEWSWIRE) -- Indaptus Therapeutics, Inc. (Nasdaq: INDP) ("Indaptus" or the...
Globe Newswire
7 months ago
NEW YORK, June 03, 2022 (GLOBE NEWSWIRE) -- Indaptus Therapeutics, Inc. (Nasdaq: INDP) ("Indaptus" or the "Company), today announced that Jeffrey A. Meckler, Chief Executive Officer of Indaptus, will present a corporate overview at the Jefferies Healthcare Conference on Friday, June 10, 2022 at 12:...
Globe Newswire
8 months ago
Former Worldwide Head of Licensing and Acquisition and Knowledge Management at Merck & Co., where he led the completion of more than150 business development transactionsFormer Global Head of Infectious Diseases for Johnson & Johnson PharmaceuticalsFormer Venture Partner at Flagship Pioneering, as ...
Globe Newswire
8 months ago
Announces Submission of Investigational New Drug (IND) Application for Decoy20 On Track to Initiate Phase 1 Clinical Trial of Decoy20 for Treatment of Solid Tumors in Second Half of 2022 NEW YORK, May 12, 2022 (GLOBE NEWSWIRE) -- Indaptus Therapeutics, Inc. (Nasdaq: INDP) ("Indaptus" or the "Company...